^
    Back
    Association details:
    Biomarker:RAS wild-type
    Cancer:Colorectal Cancer
    Drug Class:EGFR inhibitor +
    VEGF inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO-GI 2022
    Title:

    Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study

    Published date:
    06/29/2022
    Excerpt:
    The median PFS values of the cohorts who continued to receive 5FU/LV + anti-EGFR /VEGF, anti-EGFR/VEGF single agent, 5FU/LV single agent, and combination therapy without maintenance therapy were found as 16.8, 14.3, 15.8, and 11.8 months, respectively (p < 0.001)....In a “real life” setting, among the treatment strategies following the anti-EGFR/VEGF-based doublet first-line induction regimen in RAS wild-type mCRC patients, the combination of 5FU/LV + biologic as maintenance therapy emerges as the most widely adopted and effective regimen with survival advantage.
    Secondary therapy:
    5-fluorouracil + capecitabine
    DOI:
    10.1016/j.annonc.2022.04.182